Arcus Biosciences, Inc. (RCUS)

Environment story

Arcus is a clinical-stage biopharmaceutical company with limited direct operational environmental footprint typical of pre-commercial biotech firms. The company has not disclosed Scope 1, Scope 2, or Scope 3 emissions data, nor has it published a net-zero target or sustainability report. No material environmental controversies, toxic-waste incidents, or resource-depletion litigation are documented in available filings. The lack of disclosed ESG metrics and climate commitments results in a moderate environmental score reflecting absence of greenwashing risk but also absence of proactive decarbonization strategy.

Social story

Arcus operates as a research-driven biotech entity without disclosed workforce diversity metrics, CEO-to-worker pay ratios, or union relations status in available SEC filings. The 10-K contains no mention of labor disputes, NLRB complaints, or supply-chain human-rights audits. The company relies on third-party contract research organizations (CROs) and manufacturers for clinical operations, with no documented controversies regarding labor practices or supply-chain ethics. Absence of disclosed diversity targets and pay-equity commitments limits social pillar scoring; no active negative labor practices identified.

Governance story

Arcus maintains a board with three Gilead-designated directors per the Investor Rights Agreement (amended 2024). The 10-K does not disclose total board size, independence percentage, or dual-class share structure; standard single-class common stock structure is implied by filing language. No material lobbying expenditures targeting environmental deregulation or consumer-protection rollbacks are documented. The company has not faced significant antitrust, financial-fraud, or FDA consent decrees. Gilead's 25.1% ownership stake (as of December 31, 2025) and board representation create concentration of influence, but do not indicate governance failure. Absence of disclosed board-independence metrics and material regulatory fines prevents a higher score.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Arcus Biosciences, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Arcus Biosciences, Inc. in the app for interactive charts and portfolio building.

More in Healthcare